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Objectives: Brazil ministry of health guidance for diabetes management allows 
for an insulin needle to be reused 8 times. Reuse has been associated with lipo-
hypertrophy. Additionally, diabetes patients with lipohypertrophy require higher 
doses of insulin. This analysis demonstrates potential cost savings from syringe 
reuse reduction in Brazil. MethOds: A budget impact model was created to dem-
onstrate the relationship between lower syringe reuse and lipohypertrophy rates. 
It was assumed 90% of patients use syringes in Brazil. An international survey 
suggests the lipohypertrophy rate is 48%. Another study showed increasing reuse 
correlates to a higher ratio of lipohypertrophy presence. With estimates including 
additional insulin requirements for lipohypertrophy, cost of insulin, and annual 
cost and volume of syringes, the difference between insulin wasted from lipohyper-
trophy and the cost associated with reducing reuse rate was calculated. Results: 
The estimated insulin injecting population with lipohypertrophy using syringes in 
Brazil is 691,200. If these patients require 15 units more insulin/day and the cost/
unit is $0.03, then the cost of excess insulin is $113.5 million/yr. The difference in 
rate of lipohypertrophy between reusing 8x (rate of 5.5) and reusing 4x (rate of 2.2) 
is a factor of 2.5. Based on estimated cost, volume, and currently allowed reuse 
rate, Brazil spends approximately $22.8 million on insulin syringes. If a reuse rate 
of 4x was implemented ($45.6 million), Brazil could anticipate a lipohypertrophy 
reduction of 28.8%, and a $68.1 million decrease in excess insulin. The savings on 
excess insulin and the incremental investment in syringes ($22.8 million) Resultsin 
a total savings of $45.3 million/yr. cOnclusiOns: The current acceptable reuse rate 
in Brazil, 8x, may be driving increased diabetes management costs. Best practice 
advocates single use. However, if Brazil cuts their reuse guidance in half, they can 
save $45.3 million/yr from reduced insulin waste.
PMD6
BuDget iMPact analysis of DRug coateD Balloon vs. PeRcutaneous 
tRansluMinal Balloon angioPlasty in tHe tReatMent of PeRiPHeRal 
aRteRial Disease in loweR liMBs in BRazil
Pepe C1, Fahham L2, Follador W3, Valencia J4, Orozco JJ5
1Grupo Resulta, São Paulo, Brazil, 2Sense Company, São Paulo, Brazil, 3Medtronic, São Paulo, 
Brazil, 4Medtronic, Miami, FL, USA, 5Medtronic, Medellin, Colombia
Objectives: Budget Impact analysis (BIA) of Drug Coated Balloon (DCB) vs. 
Percutaneous Transluminal Balloon Angioplasty (PTA) in the treatment of 
Peripheral Arterial Disease in lower limbs in Brazil. MethOds: A BIA was per-
formed to assess the incremental budget impact of the incorporation, to the 
Brazilian public healthcare system, of a method of PTA using a drug coated bal-
loon compared to the currently available technology, using an standard balloon, 
on the treatment of the peripheral arterial disease, in a 5 years’ time horizon. The 
total amount of PTA procedures on the system was extracted from DATASUS, a 
nation-wide, anonymous, public healthcare claims database, between 2008 and 
2013. Based on this data, the eligible population was projected linearly for the years 
between 2014 and 2019. Total costs (angioplasty plus surgical revascularization in 
case of a TLR) per procedure were based on an analytic decision model (R$ 4,415.70 
(DCB); R$ 3,720.03 (PTA)). It was assumed that, after the incorporation, all patients 
eligible to a PTA will undergo the procedure using a DCB instead of the standard 
balloon. Results: The DCB incorporation showed an impact of R$ 1.9 million on 
the first year (2015) and reached a total amount of R$ 11.8 million in 5 years. The 
projected impact for the year of 2015 (R$ 1.9 million) represents less than 0.01% of 
the budget destined to hospital and ambulatory assistance. cOnclusiOns: The 
incorporation of DCB for the treatment of Peripheral Arterial Disease in Lower 
Limbs in the Brazilian public healthcare system has low budget impact and it 
would represent less than 0.01% of the budget destined to hospital and ambula-
tory assistance.
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Objectives: The objective of this study is to investigate the economic impact per 
patient using NT-proBNP test to guide the diagnostic assessment and management 
of dyspneic patients in the Emergency Department in Brazil and Mexico. MethOds: 
A cost tool was developed based on a decision tree from Siebert study. It was evalu-
ated the standard clinical assessment (strategy 1) with assessment guided by 
NT-proBNP (strategy 2), from a payer’s perspective. The direct medical costs were 
based on the DATASUS (Departamento de Informática do Sistema Único de Saúde – 
Brazil) and IMSS (Instituto Mexicano del Seguro Social – Mexico) databases converted 
to 2015 US dollars (USD). The time horizon was 60 days. Additionally, the sensitivity 
analysis was performed with a variation of 10%. Results: Based on Siebert study, 
the optimal use of NT-pro-BNP strategy reduces the use of echocardiography from 
25% to 10.5% and the average of hospitalization length from 4.41 days to 3.88 days. 
Therefore, according to our cost tool for Brazil, in the base case scenario, the sav-
ings per patient is $218.15, after applying the sensitivity analysis in the best case 
scenario the savings achieved is $385.23, and in the worst case is $51.07. A similar 
result could be achieved in Mexico, in the base case scenario the savings per patient 
is $218.96, while with the sensitivity analysis the savings reached $388.55 for the 
best case scenario, and $74.50 for the worst case. cOnclusiOns: The optimal use of 
NT-proBNP test could improve the management of patients with acute Heart Failure 
according to our analysis. Moreover, it demonstrated incremental value in diagnosis 
which may result in improved therapeutic decisions and savings for both countries.
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Objectives: Cervical cancer (CC) takes the 3rd place among women cancers glob-
ally, accounting for more than quarter of a million deaths annually. In Ukraine it 
takes the 2nd place of cancers among women aged 15 to 44, accounting for more 
than 2000 deaths each year. Gradual increase of CC incidence rates during the previ-
ous decade is concurrently followed by the decrease of a median age of diagnosis. 
Incidence rates for CC in Ukraine are estimated to be at least two times higher 
than in countries with well-organized cervical screening programs. Thus the aim 
of this study is to evaluate the most efficient cervical screening strategies using 
“cost-utility” method. MethOds: “Cost-utility”-based analysis and evaluation are 
based on the Resultsof own clinical and laboratory studies of 1257 cervical samples 
(HPV DNA tests and cytological diagnostics) from women aged 19 – 65 (mean age 
30.68 (±7.72)), living in different regions of Ukraine. Statistical and mathematical 
Methodsare used for modeling the utility function of a number of diagnostic strat-
egies. Analytical representation and evaluation of the data was performed using 
MATLAB Simulink r2014a software package. Results: Initial hypothesis of the 
utility function form for HPV DNA and cytological tests was put forward. It was 
assumed that the first test has a maximum utility at a defined age limit due to the 
age-dependent increase of the probability of cytological test being positive. This 
Resultsin reduction of the predictive utility of HPV DNA test. The utility function of 
cytological test must resemble cumulative sigmoid function. Stated hypothesis was 
verified on the data on HPV DNA presence in normal cytology and cervical intraepi-
thelial lesions using Methodsof mathematical modeling. cOnclusiOns: The study 
confirmed given hypothesis. The obtained Resultscan be used in “cost-utility”-based 
method of pharmacoeconomic analysis of different cervical screening strategies
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Objectives: The ventricular drainage of the cerebrospinal fluid (CSF) is an essen-
tial procedure in the care of patients with hydrocephalus and intracranial hyper-
tension. However, the literature shows evidences of an infection rate (IR) of 5% to 
10%. Infections can cause neurological sequelae and death. To reduce the risk of 
contamination antibiotic-impregnated catheters (AIC) are indicated. The aim of 
this study is to systematic review (SR), the efficacy of these catheters. MethOds: 
The electronic databases, MEDLINE via Pubmed, The Cochrane Central Register of 
Controlled Trials, The Cochrane Library, LILACS, CRD and EMBASE were reviewed 
until June, 2013. No language and time limits were applied. Meta-analysis, SR 
and RCTs in patients using AIC in the hydrocephalus treatment with internal 
or external shunt comparing to standard catheter (SC) were included in this 
study. Results: 232 records were identified. 45 studies were revaluated. 4 met 
the inclusion criteria – 3 SR and 1 RCT. The first SR evaluated 14 studies. Among the 
9,049 cases evaluated, SC and AIC presented an IR of 7.0% and, 3.5% respectively. 
The second SR evaluated 2,664 cases and observed a global and pediatric IR of 7.2% 
(SC) and 3.3% (AIC) and 11.2% (SC) and 5.0% (AIC). The third SR showed though a 
meta-analysis, similar Resultsfor the adult and pediatric population and included 
the neonate where they observed a significant difference for the AIC in internal 
shunts: RR:0.37; IC:0.16-0.86; p= 0.02. The RCT evaluated the IR for SC and AIC and 
found a not statistically significant lower IR in the AIC, probably because of the 
low global IR. cOnclusiOns: The studies suggest AIC reduces infections related 
to drainage especially in the pediatric population.
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Objectives: The aim of this study is to estimate, in Chile, the clinical and budget 
impact of cervical cancer primary screening with a HPV-16/18 genotyping test which 
simultaneously detects 12 other high-risk HPV types. MethOds: A decision tree 
framework was used to model the screening and diagnosis of cervical cancer to com-
pare three strategies: (1) Cytology alone – Screening Interval (SI): 3 years; (2) Pooled 
HPV with reflex cytology – SI: 5 years; (3) HPV with 16/18 genotyping and reflex 
cytology (cobas® 4800) – SI: 5 years, from a payer’s perspective. The impact model 
was run by having the women cohort progress through the model with 2 screening 
cycles. In addition, the screening and cancer treatment costs were calculated from 
FONASA public data (Fondo Nacional de Salud) reported in 2014 converted to US dol-
lars (USD). Results: The Budget Impact Model indicates that, when comparing the 
Strategy 2 and 3 to Strategy 1 there is an increase of ≥ CIN2 (Cervical Intraepithelial 
Neoplasia) cases detected, treated and a reduction at the number of patients pro-
gressing to cervical cancer. When comparing the strategy 2 to strategy 1, the model 
estimated savings of 1.9% at the annual costs, including screening, diagnosis and 
treatment. There is also a decrease of 25% and 33% at the incidence of Cervical 
Cancer and Mortality Rate, respectively. Better clinical Resultscould be achieved 
when the strategy 3 is implemented. An additional investment of only 0.37% at the 
annual budget would be necessary to decrease the incidence of Cervical Cancer by 
43% and the mortality rate by 54% in Chile. cOnclusiOns: This analysis suggests 
that the use of the HPV genotyping test (strategy 3) is a potential effective manage-
ment strategy, given that the clinical impacts are highly positives and budgetary 
impact is basically neutral, comparing to the current screening program in Chile.
